Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
March 13, 2017 08:15 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
March 08, 2017 08:15 ET
|
Abeona Therapeutics Inc
Abeona’s Fourth Gene Therapy Program to Receive EMA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
March 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
March 03, 2017 07:44 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 03, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
February 21, 2017 07:48 ET
|
Abeona Therapeutics Inc
Company CEO and COO Presentations to be Held on Wednesday, February 22ndNEW YORK and CLEVELAND, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading...
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
February 17, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO):ABO-102 gene therapy well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days...
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
February 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
Multiple Oral Platform Presentations and Poster Sessions Highlighting Gene Therapy Programs, Tuesday, February 14th through Thursday, February 16th NEW YORK and CLEVELAND, Feb. 07, 2017 (GLOBE...
Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
February 01, 2017 07:43 ET
|
Abeona Therapeutics Inc
ABO-102, the leading clinical gene therapy program for Sanfilippo syndrome type A patients, has demonstrated central nervous system (CNS) and peripheral organ disease biopotencyFirst high dose cohort...
Insight Pharma Reports' Gene Therapy Market Report: Moving Toward Commercialization
September 23, 2016 13:00 ET
|
Insight Pharma Reports
NEEDHAM, MA--(Marketwired - September 23, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, releases "Gene Therapy: Moving Toward Commercialization" an in-depth life science market...
Gene Therapy: Moving Toward Commercialization
May 11, 2016 10:50 ET
|
Insight Pharma Reports
NEEDHAM, MA--(Marketwired - May 11, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, releases "Gene Therapy: Moving Toward Commercialization" an in-depth life science market...